Allena Pharmaceuticals, Inc. Depreciation & Amortization Growth

Depreciation & Amortization Growth of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Depreciation & Amortization Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Depreciation & Amortization Growth for the quarter ending March 31, 2022 was 92.31% (a -49.76% decrease compared to previous quarter)
  • Year-over-year quarterly Depreciation & Amortization Growth increased by 2.02%
  • Annual Depreciation & Amortization Growth for 2021 was 118.67% (a 6349.46% increase from previous year)
  • Annual Depreciation & Amortization Growth for 2020 was 1.84% (a -98.31% decrease from previous year)
  • Annual Depreciation & Amortization Growth for 2019 was 108.97% (a -512.45% decrease from previous year)
  • Twelve month Depreciation & Amortization Growth ending March 31, 2022 was 122.63% (a 3.34% increase compared to previous quarter)
  • Twelve month trailing Depreciation & Amortization Growth increased by 235.7% year-over-year
Trailing Depreciation & Amortization Growth for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
122.63% 118.67% 72.12% 36.53%
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Depreciation & Amortization Growth of Allena Pharmaceuticals, Inc.

Most recent Depreciation & Amortization Growthof ALNA including historical data for past 10 years.

Interactive Chart of Depreciation & Amortization Growth of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Depreciation & Amortization Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 92.31%
2021 183.72% 140.0% 90.48% 58.54% 118.67%
2020 2.38% -4.76% 7.69% 2.5% 1.84%
2019 23.53% 147.06% 387.5% 110.53% 108.97%
2018 70.0% -10.53% -63.64% -57.78% -26.42%
2017 -64.91% -85.71% -75.56% 136.84% -46.73%
2016 185.0% 600.0% 103.06%
2015 309.09% -50.75%

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.